Autor: Merike Kungla • 19. mai 2011
Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.
Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business
OSAKA, Japan, and ZURICH,
Switzerland, May 19, 2011 - Takeda Pharmaceutical Company Limited ("Takeda",
TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has
reached an agreement with the shareholders of Nycomed in which Takeda will
acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free,
debt-free basis. The boards of directors of each company unanimously approved
the transaction which is expected to be completed within 90 to 120 days, making
it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The
purchase would exclude Nycomed's U.S. dermatology business.
The sellers are comprised of a consortium of private equity funds led by Nordic Capital Funds V and VI ("Nordic Capital"), including DLJ Merchant Banking Partners (a Credit Suisse affiliate), Coller International Partners IV and V, and Avista Capital Partners.
This transformational transaction is a strategic fit with Takeda's sustainable growth strategy as it was outlined in its 2011-2013 Mid-Range Plan. Takeda has its strong presence in the Japanese and U.S. markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialization capability. The acquisition includes the roflumilast franchise (Daxas®; trade name in Europe), a first-in-class treatment for chronic obstructive pulmonary disease (COPD), which is expected to be a major source of revenue growth for Takeda. In addition, the acquisition will bring Takeda an immediate and stable increase in cash flow with Nycomed's more than 2.8 billion Euro in annual revenue, excluding the U.S. Dermatology business.
Liitu Meditsiiniuudiste uudiskirjaga!
Liitu Meditsiiniuudiste uudiskirjaga!